Annual balance sheet for XBiotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 237 | 217 | 200 | 173 | 126 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 8.95 | 1.76 | 0.935 | 0.858 | 0.36 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 247 | 220 | 202 | 175 | 127 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 28.3 | 26.3 | 24.9 | 24.5 | 23.1 |
| Other Long Term Assets | |||||
| Total Assets | 275 | 246 | 227 | 199 | 150 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.45 | 4.07 | 6.1 | 15.1 | 7.93 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 5.79 | 5.7 | 7.77 | 16.8 | 9.73 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 269 | 240 | 219 | 182 | 140 |
| Total Liabilities & Shareholders' Equity | 275 | 246 | 227 | 199 | 150 |
| Total Common Shares Outstanding |